• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Glaukos Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/3/25 4:23:59 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care
    Get the next $GKOS alert in real time by email
    0001192448false00011924482025-05-292025-05-29

    ​

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ​

    FORM 8-K

    ​

    CURRENT REPORT

    ​

    Pursuant to Section 13 or 15(d) of

    The Securities Exchange Act of 1934

    ​

    Date of Report (Date of earliest event reported): May 29, 2025

    Glaukos Corporation

    (Exact name of registrant as specified in its charter)

    ​

    Delaware

        

    001-37463

        

    33-0945406

    (State or other jurisdiction

    ​

    (Commission

    ​

    (I.R.S. Employer

    of incorporation)

    ​

    File Number)

    ​

    Identification No.)

    ​

    ​

    One Glaukos Way

     

    Aliso Viejo, California

    ​

    92656

     

    (Address of principal executive offices)

     

    (Zip Code)

    ​

    Registrant’s telephone number, including area code: (949) 367-9600

    ​

    Not Applicable

    (Former name or former address, if changed since last report.)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  Emerging growth company ☐

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

    ​

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class:

        

    Trading Symbol

        

    Name of each exchange on which registered:

    Common Stock

    ​

    GKOS

    ​

    New York Stock Exchange

    ​

    ​

    ​

    Item 5.07. Submission of Matters to a Vote of Security Holders.

    The annual meeting of stockholders (the “Annual Meeting”) of Glaukos Corporation (the “Company”) was held on May 29, 2025. At the Annual Meeting, the Company’s stockholders voted on three proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 15, 2025.

    The final voting results for each matter submitted to a vote of stockholders at the Annual Meeting are as follows:

    Proposal 1. The election of three Class I directors to hold office until the 2028 annual meeting of stockholders and until their respective successors are duly elected and qualified:

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

        

    For

        

    Withheld

        

    Broker
    Non-Votes

    Mark J. Foley

    ​

    38,866,634

    ​

    11,305,858

    ​

    3,221,029

    David F. Hoffmeister

    ​

    46,794,939

    ​

    3,377,553

    ​

    3,221,029

    Gilbert H. Kliman, M.D.

    ​

    42,495,145

    ​

    7,677,347

    ​

    3,221,029

    ​

    ​

    Proposal 2. The non-binding advisory vote regarding approval of the compensation of the Company’s named executive officers:

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    For

        

    Against

        

    Abstain

        

    Broker
    Non-Votes

    48,971,169

    ​

    1,143,789

    ​

    57,534

    ​

    3,221,029

    ​

    Proposal 3. The ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025:

    1,

    ​

    ​

    ​

    ​

    For

        

    Against

        

    Abstain

    53,222,095

    ​

    140,642

    ​

    30,784

    ​

    There were no broker non-votes on Proposal 3.

    ​

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

    ​

    GLAUKOS CORPORATION

    ​

    ​

    By:

    /s/ Robert L. Davis

    ​

    ​

    Name:

    Robert L. Davis

    ​

    ​

    Title:

    Senior Vice President, General Counsel & Business Development

    Date: June 3, 2025

    ​

    Get the next $GKOS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $GKOS

    DatePrice TargetRatingAnalyst
    5/1/2025$86.00Overweight → Equal Weight
    Wells Fargo
    2/19/2025$140.00 → $200.00Neutral → Outperform
    Mizuho
    12/11/2024$132.00 → $162.00Neutral → Buy
    Citigroup
    12/6/2024$182.00Buy
    UBS
    12/2/2024$120.00Equal-Weight → Underweight
    Morgan Stanley
    7/10/2024$132.00Buy → Neutral
    Citigroup
    5/6/2024$84.00 → $125.00Hold → Buy
    Jefferies
    12/21/2023$66.00 → $91.00Neutral → Overweight
    JP Morgan
    More analyst ratings

    $GKOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hoffmeister David F exercised 25,000 shares at a strike of $32.00, increasing direct ownership by 361% to 31,918 units (SEC Form 4)

      4 - GLAUKOS Corp (0001192448) (Issuer)

      6/13/25 7:43:41 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • Director Foley Mark J was granted 2,972 shares, increasing direct ownership by 64% to 57,221 units (SEC Form 4)

      4 - GLAUKOS Corp (0001192448) (Issuer)

      6/2/25 4:44:12 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • Director Hoffmeister David F was granted 2,665 shares, increasing direct ownership by 63% to 6,918 units (SEC Form 4)

      4 - GLAUKOS Corp (0001192448) (Issuer)

      6/2/25 4:43:25 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care

    $GKOS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies

      Regulatory Clearances Support Glaukos' Plans to Advance and Accelerate its Interventional Glaucoma Initiatives Globally Marks the Company's First Regulatory Clearances Under the New EU Regulatory Framework Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has received European Union (EU) Medical Device Regulation (MDR) certification for iStent infinite®, along with several of its other leading micro-invasive glaucoma surgery (MIGS) technologies, including iStent inject® W. Glaukos' iStent® trabecular micro-bypass stenting platfor

      6/25/25 4:05:00 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • NYSE Content Advisory: Pre-Market update + S&P 500 trades within 1% of record

      NEW YORK, June 25, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Kristen Scholer delivers the pre-market update on June 25th Equities are little changed Wednesday morning after jumping by more than 1% on Tuesday. The DOW gained over 500 points while the S&P 500 sits just shy of a record high.Driving those gains were easing tensions in the Middle East, resulting in crude oil prices falling by approximately 5% during Tuesday's session. President Trump announced a ceasefire agreement on Monday night.Fed

      6/25/25 8:55:00 AM ET
      $GKOS
      $ICE
      $JBS
      Medical/Dental Instruments
      Health Care
      Investment Bankers/Brokers/Service
      Finance
    • Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell

      Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it will celebrate the 10th anniversary of its Initial Public Offering (IPO) listing on the New York Stock Exchange (NYSE) by ringing The Closing Bell at 4:00 p.m. ET today, Wednesday, June 25, 2025. "Ringing the NYSE closing bell today is a proud and humbling moment for our company, commemorating ten years since our IPO and celebrating the tremendous progress we've made in advancing our mission to transform vision therapies for the benefit of patients suffering from chronic eye disease

      6/25/25 7:00:00 AM ET
      $GKOS
      Medical/Dental Instruments
      Health Care

    $GKOS
    Leadership Updates

    Live Leadership Updates

    See more
    • OnCusp Therapeutics Announces Appointment of Robert Forrester and Chau Khuong to Board of Directors

      NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneur Robert Forrester and venture capitalist Chau Khuong as independent board directors. "We are delighted to have Robert and Chau, two seasoned leaders with a wealth of insights and expertise, to join OnCusp's Board. Both are highly regarded and deeply connected in the biotech and investment community," said Dr. Bing Yuan, Chairman and CEO of OnCusp. "Each of these individuals brings unique skill sets to our Board and will be instrumental to advancing OnCusp through se

      1/4/23 8:00:00 AM ET
      $BLU
      $GKOS
      $INSP
      $NTLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • Glaukos Announces Retirement of William J. Link, Ph.D., as Chairman of the Board and Election of Thomas W. Burns as New Chairman and Mark J. Foley as Lead Independent Director

      Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that William J. Link, Ph.D., will be retiring as Chairman of the Board, effective December 31, 2021. Dr. Link joined Glaukos' Board and has served as Chairman since June 2001. In connection with Dr. Link's retirement, the Board has appointed Thomas W. Burns, Glaukos' President and Chief Executive Officer and a director on the Board since 2002, to serve as the company's Chairman of the Board, effective upon Dr. Link's retirement on December 31, 2021. Mr. Burns will continue to serve as th

      12/20/21 4:15:00 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • Glaukos Appoints Denice Torres and Dr. Leana Wen to its Board of Directors

      SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the appointment of Denice Torres and Dr. Leana Wen to its Board of Directors, effective today. With the addition of these two directors, Glaukos’ Board of Directors will be comprised of nine directors, eight of whom are independent. “We are delighted and honored to welcome these highly accomplished professionals to the Glaukos Board. Each of these extraordinary women brings a wealth of relevant experience, perspective, leadership and wis

      3/1/21 4:10:00 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care

    $GKOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Glaukos Corporation

      SC 13G/A - GLAUKOS Corp (0001192448) (Subject)

      11/14/24 1:21:45 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Glaukos Corporation (Amendment)

      SC 13G/A - GLAUKOS Corp (0001192448) (Subject)

      2/14/24 3:55:55 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Glaukos Corporation (Amendment)

      SC 13G/A - GLAUKOS Corp (0001192448) (Subject)

      2/13/24 5:41:34 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care

    $GKOS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Glaukos downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Glaukos from Overweight to Equal Weight and set a new price target of $86.00

      5/1/25 7:44:23 AM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • Glaukos upgraded by Mizuho with a new price target

      Mizuho upgraded Glaukos from Neutral to Outperform and set a new price target of $200.00 from $140.00 previously

      2/19/25 7:02:55 AM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • Glaukos upgraded by Citigroup with a new price target

      Citigroup upgraded Glaukos from Neutral to Buy and set a new price target of $162.00 from $132.00 previously

      12/11/24 7:52:08 AM ET
      $GKOS
      Medical/Dental Instruments
      Health Care

    $GKOS
    SEC Filings

    See more
    • Glaukos Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - GLAUKOS Corp (0001192448) (Filer)

      6/3/25 4:23:59 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Glaukos Corporation

      SD - GLAUKOS Corp (0001192448) (Filer)

      5/30/25 4:45:35 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • Glaukos Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - GLAUKOS Corp (0001192448) (Filer)

      5/14/25 7:00:17 AM ET
      $GKOS
      Medical/Dental Instruments
      Health Care

    $GKOS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for IDOSE TR issued to GLAUKOS CORP

      Submission status for GLAUKOS CORP's drug IDOSE TR (ORIG-1) with active ingredient TRAVOPROST has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 218010, Application Classification: Type 3 - New Dosage Form

      12/15/23 11:41:09 AM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • FDA Approval for TRAVOPROST issued to GLAUKOS CORP

      Submission status for GLAUKOS CORP's drug TRAVOPROST (ORIG-1) with active ingredient TRAVOPROST has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 218010, Application Classification: Type 3 - New Dosage Form

      12/14/23 7:41:03 AM ET
      $GKOS
      Medical/Dental Instruments
      Health Care

    $GKOS
    Financials

    Live finance-specific insights

    See more
    • Glaukos Announces First Quarter 2025 Financial Results

      Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2025. Key highlights include: Record net sales of $106.7 million in Q1 2025 increased 25% year-over-year on a reported basis and 26% year-over-year on a constant currency basis. Glaucoma record net sales of $88.1 million in Q1 2025 increased 31% year-over-year. U.S. Glaucoma record net sales of $59.1 million in Q1 2025 increased 41% year-over-year. Gross margin of approximately 77% and non-GAAP gross margin of approximately

      4/30/25 4:05:00 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

      Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2025 financial results after the market close on Wednesday, April 30, 2025. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on April 30, 2025. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 800-715-9871 (U.S.) or 646-307-1963 (Int

      4/9/25 7:00:00 AM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

      Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2024. Key highlights include: Record net sales of $105.5 million in Q4 2024 increased 28% year-over-year. Glaucoma record net sales of $84.1 million in Q4 2024 increased 39% year-over-year. Gross margin of approximately 73% and non-GAAP gross margin of approximately 82% in Q4 2024. Net sales of $383.5 million in FY 2024 increased 22% year-over-year. Introduced 2025 net sales guidance of $475 million to $4

      2/20/25 4:05:00 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care